Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC). Despite the efficacy of sorafenib, the response rate varies in patients with advanced HCC. We retrospectively analyzed a series of Korean patients with advanced HCC with complete remission (CR) after sorafenib therapy. Methods: In total, 523 patients with advanced HCC were treated with sorafenib in 3 large tertiary referral hospitals in Korea. A survey was conducted to collect data on patients who experienced CR after sorafenib monotherapy, and their medical records and follow-up data were analyzed. The tumor response and recurrence rates were assessed by radiologic study, based on modified response evaluation criteria in solid tumors. Results: Seven patients with advanced HCC experienced CR after sorafenib therapy. The median time to tumor disappearance and the median disease-free survival time were 3 months and 9 months, respectively. HCC recurrence was identified in three cases (42.9%). Of these, two patients discontinued sorafenib before or after achieving CR and the other patient continued sorafenib after achieving CR. HCC recurred at 3, 10, and 42 months after CR in these three patients. Three patients needed dose reduction for toxicity and adverse events. Conclusions: Though CR was achieved after sorafenib therapy in patients with advanced HCC, the recurrence rate was relatively high. Subsequent strategies to reduce a chance of recurrence after sorafenib therapy are required to investigate. (Clin Mol Hepatol 2015;21:287-294)
Abstract
Background/Aims: Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC). Despite the efficacy of sorafenib, the response rate varies in patients with advanced HCC. We retrospectively analyzed a series of Korean patients with advanced HCC with complete remission (CR) after sorafenib therapy. Methods: In total, 523 patients with advanced HCC were treated with sorafenib in 3 large tertiary referral hospitals in Korea. A survey was conducted to collect data on patients who experienced CR after sorafenib monotherapy, and their medical records and follow-up data were analyzed. The tumor response and recurrence rates were assessed by radiologic study, based on modified response evaluation criteria in solid tumors. Results: Seven patients with advanced HCC experienced CR after sorafenib therapy. The median time to tumor disappearance and the median disease-free survival time were 3 months and 9 months, respectively. HCC recurrence was identified in three cases (42.9%). Of these, two patients discontinued sorafenib before or after achieving CR and the other patient continued sorafenib after achieving CR. HCC recurred at 3, 10, and 42 months after CR in these three patients. Three patients needed dose reduction for toxicity and adverse events. Conclusions: Though CR was achieved after sorafenib therapy in patients with advanced HCC, the recurrence rate was relatively high. Subsequent strategies to reduce a chance of recurrence after sorafenib therapy are required to investigate. (Clin Mol Hepatol 2015;21:287-294)
참고문헌 (29)
- Parkin DM, "Global cancer statistics, 2002", CA Cancer J Clin, 55, pp.74~108 (2005)
- Lopez PM, "Systematic review : evidencebased management of hepatocellular carcinoma-an updated analysis of randomized controlled trials", Aliment Pharmacol Ther, 23, pp.1535~1547 (2006)
- Llovet JM, "Hepatocellular carcinoma", Lancet, 362, pp.1907~1917 (2003)
- Nowak AK, "Systemic therapy for advanced hepatocellular carcinoma : a review", Eur J Cancer, 40, pp.1474~1484 (2004)
- Wilhelm SM, "BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF", MEK, Cancer Res, pp.2004, 64[DOI]
- Chang YS, "Sorafenib(BAY 43-9006)inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models", Cancer Chemother Pharmacol, 59, pp.561~574 (2007)
- Wilhelm SM, "Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling", Mol Cancer Ther, 7, pp.3129~3140 (2008)
- Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
- Cheng AL, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial", Lancet Oncol, 10, pp.25~34 (2009)
- Bruix J, "Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)
- European Association For The Study Of The Liver, "EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma", J Hepatol, 56, pp.908~943 (2012)
- Kudo M, "Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan", Oncology, 78(1), pp.154~166 (2010)
- Korean Liver Cancer Study Group and National Cancer Center, "Practice guidelines for management of hepatocellular carcinoma 2009", Korean J Hepatol, 15, pp.391~423 (2009)
- Lencioni R, "Modified RECIST(mRECIST)assessment for hepatocellular carcinoma", Semin Liver Dis, 30, pp.52~60 (2010)
- So BJ, "Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis : a case report", J Hematol Oncol, 1, pp.18~ (2008)
- Irtan S, "Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection", Liver Int, 31, pp.740~743 (2011)
- Curtit E, "Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report", J Clin Oncol, 29, pp.e330~e332 (2011)
- Wang SX, "Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib : a case report", Target Oncol, 5, pp.59~63 (2010)
- Inuzuka T, "Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib : a case report", Oncology, 81, pp.152~157 (2011)
- Chelis L, "Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART?", A case report. Med Oncol, 28, pp.S165~S168 (2011)
- Sacco R, "Complete response for advanced liver cancer during sorafenib therapy : case report", BMC Gastroenterol, 11, pp.4~ (2011)
- Yeganeh M, "Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib", Am J Transplant, 9, pp.2851~2854 (2009)
- Ahn SY, "Sustained remission over 36 months of advanced hepatocellular carcinoma after shortterm sorafenib therapy", Dig Dis Sci, 58, pp.1428~1432 (2013)
- Kim MS, "Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report", World J Gastrointest Oncol, 15(5), pp.38~42 (2013)
- Shiba S, "Characteristics of 18patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib", Hepatol Res, 44, pp.1268~1276 (2014)
- Yau T, "The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib", Oncologist, 16, pp.1270~1279 (2011)
- Personeni N, "Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma", J Hepatol, 57, pp.101~107 (2012)
- Li Q, "Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma", J Exp Clin Cancer Res, 25, pp.403~409 (2006)
- Novi M, "Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma", Am J Gastroenterol, 104, pp.1852~1854 (2009)